Compare TMC & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMC | CDNA |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2020 | 2007 |
| Metric | TMC | CDNA |
|---|---|---|
| Price | $3.96 | $45.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $8.85 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 4.6M | 1.1M |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.00 | N/A |
| EPS | 0.19 | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ $19.84 | $21.77 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $3.40 | $11.27 |
| 52 Week High | $11.35 | $49.76 |
| Indicator | TMC | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 63.69 |
| Support Level | $3.89 | $16.70 |
| Resistance Level | $4.81 | $49.76 |
| Average True Range (ATR) | 0.27 | 2.29 |
| MACD | 0.02 | -0.39 |
| Stochastic Oscillator | 36.51 | 70.31 |
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.